Your browser doesn't support javascript.
loading
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer.
Kapil, Ansh; Spitzmüller, Andreas; Brieu, Nicolas; Haneder, Susanne; Shumilov, Anatoliy; Meier, Armin; Cecchi, Fabiola; Barkell, Alice; Harder, Nathalie; Mittermaier, Katrin; Hidalgo-Sastre, Ana; Alleze, Regina; Schick, Markus; Schmidt, Günter; Sade, Hadassah; Tsuchihashi, Zenta; Suto, Fumitaka; Gustavson, Mark; Barrett, J Carl; Carroll, Danielle.
Afiliação
  • Kapil A; Computational Pathology, Oncology R&D, AstraZeneca, Bernhard-Wicki-Straße 5, 80636, München, Bayern, Germany. ansh.kapil@astrazeneca.com.
  • Spitzmüller A; Computational Pathology, Oncology R&D, AstraZeneca, Bernhard-Wicki-Straße 5, 80636, München, Bayern, Germany.
  • Brieu N; Computational Pathology, Oncology R&D, AstraZeneca, Bernhard-Wicki-Straße 5, 80636, München, Bayern, Germany.
  • Haneder S; Computational Pathology, Oncology R&D, AstraZeneca, Bernhard-Wicki-Straße 5, 80636, München, Bayern, Germany.
  • Shumilov A; Computational Pathology, Oncology R&D, AstraZeneca, Bernhard-Wicki-Straße 5, 80636, München, Bayern, Germany.
  • Meier A; Computational Pathology, Oncology R&D, AstraZeneca, Bernhard-Wicki-Straße 5, 80636, München, Bayern, Germany.
  • Cecchi F; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Barkell A; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Harder N; Computational Pathology, Oncology R&D, AstraZeneca, Bernhard-Wicki-Straße 5, 80636, München, Bayern, Germany.
  • Mittermaier K; Computational Pathology, Oncology R&D, AstraZeneca, Bernhard-Wicki-Straße 5, 80636, München, Bayern, Germany.
  • Hidalgo-Sastre A; Computational Pathology, Oncology R&D, AstraZeneca, Bernhard-Wicki-Straße 5, 80636, München, Bayern, Germany.
  • Alleze R; Computational Pathology, Oncology R&D, AstraZeneca, Bernhard-Wicki-Straße 5, 80636, München, Bayern, Germany.
  • Schick M; Computational Pathology, Oncology R&D, AstraZeneca, Bernhard-Wicki-Straße 5, 80636, München, Bayern, Germany.
  • Schmidt G; Computational Pathology, Oncology R&D, AstraZeneca, Bernhard-Wicki-Straße 5, 80636, München, Bayern, Germany.
  • Sade H; Computational Pathology, Oncology R&D, AstraZeneca, Bernhard-Wicki-Straße 5, 80636, München, Bayern, Germany.
  • Tsuchihashi Z; Translational Science, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.
  • Suto F; Translational Science, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.
  • Gustavson M; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Barrett JC; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Carroll D; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
Sci Rep ; 14(1): 12129, 2024 05 27.
Article em En | MEDLINE | ID: mdl-38802399
ABSTRACT
Many targeted cancer therapies rely on biomarkers assessed by scoring of immunohistochemically (IHC)-stained tissue, which is subjective, semiquantitative, and does not account for expression heterogeneity. We describe an image analysis-based method for quantitative continuous scoring (QCS) of digital whole-slide images acquired from baseline human epidermal growth factor receptor 2 (HER2) IHC-stained breast cancer tissue. Candidate signatures for patient stratification using QCS of HER2 expression on subcellular compartments were identified, addressing the spatial distribution of tumor cells and tumor-infiltrating lymphocytes. Using data from trastuzumab deruxtecan-treated patients with HER2-positive and HER2-negative breast cancer from a phase 1 study (NCT02564900; DS8201-A-J101; N = 151), QCS-based patient stratification showed longer progression-free survival (14.8 vs 8.6 months) with higher prevalence of patient selection (76.4 vs 56.9%) and a better cross-validated log-rank p value (0.026 vs 0.26) than manual scoring based on the American Society of Clinical Oncology / College of American Pathologists guidelines. QCS-based features enriched the HER2-negative subgroup by correctly predicting 20 of 26 responders.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Seleção de Pacientes / Trastuzumab Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Seleção de Pacientes / Trastuzumab Idioma: En Ano de publicação: 2024 Tipo de documento: Article